Olmesartan/Amlodipine/Hct Eg (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan/Amlodipine/Hct Eg, is a angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension in adults, often when monotherapy does not achieve target blood pressure.

GNH USA supplies Olmesartan/Amlodipine/Hct Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/Amlodipine/Hct Eg is prescribed for hypertension and related cardiovascular risk management pathways. - Hypertension: helps achieve target blood pressure when single‑agent therapy is insufficient. - Hypertensive heart disease: reduces cardiac workload and may limit disease progression. - Chronic kidney disease with hypertension: assists in slowing renal function decline associated with high blood pressure.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Peripheral edema - Flushing - Fatigue - Increased urination

Serious or Rare Side Effects: - Severe hypotension - Electrolyte disturbances (e.g., low potassium) - Acute kidney injury - Angio‑edema - Liver function abnormalities - Blood cell count changes

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal function: assess baseline creatinine and eGFR, adjust if impaired. - Electrolytes: monitor potassium and sodium levels, especially with diuretic component. - Hepatic function: use caution in patients with liver disease. - Pregnancy: contraindicated in the second and third trimesters; avoid use. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Olmesartan/Amlodipine/Hct Eg can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyper‑kalemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine exposure. - Lithium: may increase lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect. - ACE inhibitors or other ARBs: additive blood‑pressure lowering, risk of renal dysfunction. - Antidiabetic agents: monitor glucose as diuretic may affect glycemic control.